Carolyn Bertozzi (Noah Berger/AP Images)

No­bel lau­re­ate Car­olyn Bertozzi joins cell ther­a­py biotech Ace­po­dia as chief sci­en­tif­ic ad­vi­sor

Car­olyn Bertozzi helped kin­dle the spark that be­came cell ther­a­py biotech Ace­po­dia while the com­pa­ny’s co-founder, Son­ny Hsiao, was still a PhD stu­dent, work­ing in Bertozzi’s lab at UC Berke­ley.

More than a decade lat­er, the No­bel lau­re­ate has been named Ace­po­dia’s chief sci­en­tif­ic ad­vi­sor, the biotech an­nounced Mon­day.

Ace­po­dia, found­ed in 2017, is now in the clin­ic, start­ing with the first two can­di­dates from its an­ti­body-cell con­ju­gate plat­form, which pairs tar­get­ed mon­o­clon­al an­ti­bod­ies with im­mune cells that at­tack can­cer. The idea is sim­i­lar to an­ti­body-drug con­ju­gates and builds up­on ground­break­ing dis­cov­er­ies in click chem­istry that won Bertozzi the No­bel Prize in Chem­istry in 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.